Literature DB >> 31467031

Primary Human Natural Killer Cells Retain Proinflammatory IgG1 at the Cell Surface and Express CD16a Glycoforms with Donor-dependent Variability.

Kashyap R Patel1, Joel D Nott2, Adam W Barb3.   

Abstract

Post-translational modification confers diverse functional properties to immune system proteins. The composition of serum proteins such as immunoglobulin G (IgG) strongly associates with disease including forms lacking a fucose modification of the crystallizable fragment (Fc) asparagine(N)-linked glycan that show increased effector function, however, virtually nothing is known about the composition of cell surface receptors or their bound ligands in situ because of low abundance in the circulating blood. We isolated primary NK cells from apheresis filters following plasma or platelet donation to characterize the compositional variability of Fc γ receptor IIIa/CD16a and its bound ligand, IgG1. CD16a N162-glycans showed the largest differences between donors; one donor displayed only oligomannose-type N-glycans at N162 that correlate with high affinity IgG1 Fc binding whereas the other donors displayed a high degree of compositional variability at this site. Hybrid-type N-glycans with intermediate processing dominated at N45 and highly modified, complex-type N-glycans decorated N38 and N74 from all donors. Analysis of the IgG1 ligand bound to NK cell CD16a revealed a sharp decrease in antibody fucosylation (43.2 ± 11.0%) versus serum from the same donors (89.7 ± 3.9%). Thus, NK cells express CD16a with unique modification patterns and preferentially bind IgG1 without the Fc fucose modification at the cell surface.
© 2019 Patel et al.

Entities:  

Keywords:  CD16; Fc gamma receptor; glycoprotein secretion; glycoproteomics; immunoglobulin G; immunology; membranes; post-translational modifications

Mesh:

Substances:

Year:  2019        PMID: 31467031      PMCID: PMC6823852          DOI: 10.1074/mcp.RA119.001607

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  65 in total

1.  Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab.

Authors:  Jerrard M Hayes; Asa Frostell; Robert Karlsson; Steffen Müller; Silvia Míllan Martín; Martin Pauers; Franziska Reuss; Eoin F Cosgrave; Cecilia Anneren; Gavin P Davey; Pauline M Rudd
Journal:  Mol Cell Proteomics       Date:  2017-06-02       Impact factor: 5.911

2.  Glycosylation of FcgammaRIII in N163 as mechanism of regulating receptor affinity.

Authors:  Bettina Drescher; Torsten Witte; Reinhold E Schmidt
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

3.  FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

Authors:  Wu Zhang; Michael Gordon; Anne M Schultheis; Dong Yun Yang; Fumio Nagashima; Mizutomo Azuma; Heung-Moon Chang; Eva Borucka; Georg Lurje; Andy E Sherrod; Syma Iqbal; Susan Groshen; Heinz-Josef Lenz
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

4.  Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.

Authors:  Anna Maria Trotta; Alessandro Ottaiano; Carmela Romano; Guglielmo Nasti; Anna Nappi; Chiara De Divitiis; Maria Napolitano; Serena Zanotta; Rossana Casaretti; Crescenzo D'Alterio; Antonio Avallone; Daniela Califano; Rosario Vincenzo Iaffaioli; Stefania Scala
Journal:  Cancer Immunol Res       Date:  2016-01-27       Impact factor: 11.151

5.  Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

Authors:  Frédéric Bibeau; Evelyne Lopez-Crapez; Frédéric Di Fiore; Simon Thezenas; Marc Ychou; France Blanchard; Aude Lamy; Frédérique Penault-Llorca; Thierry Frébourg; Pierre Michel; Jean-Christophe Sabourin; Florence Boissière-Michot
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

6.  Interaction of human immunoglobulin G with CD16 on natural killer cells: ligand clearance, FcgammaRIIIA turnover and effects of metalloproteinases on FcgammaRIIIA-mediated binding, signal transduction and killing.

Authors:  G Mota; I Moldovan; A Calugaru; M Hirt; E Kozma; C Galatiuc; L Brasoveanu; G Boltz-Nitulescu
Journal:  Scand J Immunol       Date:  2004-03       Impact factor: 3.487

7.  A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a.

Authors:  Jacob T Roberts; Adam W Barb
Journal:  J Biol Chem       Date:  2018-10-25       Impact factor: 5.157

8.  GlycoSpectrumScan: fishing glycopeptides from MS spectra of protease digests of human colostrum sIgA.

Authors:  Nandan Deshpande; Pia H Jensen; Nicolle H Packer; Daniel Kolarich
Journal:  J Proteome Res       Date:  2010-02-05       Impact factor: 4.466

9.  Characterization of Endogenous Human FcγRIII by Mass Spectrometry Reveals Site, Allele and Sequence Specific Glycosylation.

Authors:  Nathaniel Washburn; Robin Meccariello; Jay Duffner; Kristen Getchell; Kimberly Holte; Thomas Prod'homme; Karunya Srinivasan; Robert Prenovitz; Jonathan Lansing; Ishan Capila; Ganesh Kaundinya; Anthony M Manning; Carlos J Bosques
Journal:  Mol Cell Proteomics       Date:  2018-12-17       Impact factor: 5.911

10.  Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers.

Authors:  Gordan Lauc; Jennifer E Huffman; Maja Pučić; Lina Zgaga; Barbara Adamczyk; Ana Mužinić; Mislav Novokmet; Ozren Polašek; Olga Gornik; Jasminka Krištić; Toma Keser; Veronique Vitart; Blanca Scheijen; Hae-Won Uh; Mariam Molokhia; Alan Leslie Patrick; Paul McKeigue; Ivana Kolčić; Ivan Krešimir Lukić; Olivia Swann; Frank N van Leeuwen; L Renee Ruhaak; Jeanine J Houwing-Duistermaat; P Eline Slagboom; Marian Beekman; Anton J M de Craen; André M Deelder; Qiang Zeng; Wei Wang; Nicholas D Hastie; Ulf Gyllensten; James F Wilson; Manfred Wuhrer; Alan F Wright; Pauline M Rudd; Caroline Hayward; Yurii Aulchenko; Harry Campbell; Igor Rudan
Journal:  PLoS Genet       Date:  2013-01-31       Impact factor: 5.917

View more
  12 in total

1.  Immunoglobulin G Glycosylation Changes in Aging and Other Inflammatory Conditions.

Authors:  Fabio Dall'Olio; Nadia Malagolini
Journal:  Exp Suppl       Date:  2021

Review 2.  Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation.

Authors:  Yusuke Mimura; Radka Saldova; Yuka Mimura-Kimura; Pauline M Rudd; Roy Jefferis
Journal:  Exp Suppl       Date:  2021

3.  The antibody-binding Fc gamma receptor IIIa / CD16a is N-glycosylated with high occupancy at all five sites.

Authors:  Elizabeth A Lampros; Paul G Kremer; Jesús S Aguilar Díaz de León; Elijah T Roberts; Maria Carolina Rodriguez Benavente; I Jonathan Amster; Adam W Barb
Journal:  Curr Res Immunol       Date:  2022-06-09

4.  Allotype-specific processing of the CD16a N45-glycan from primary human natural killer cells and monocytes.

Authors:  Kashyap R Patel; Jacob T Roberts; Adam W Barb
Journal:  Glycobiology       Date:  2020-07-20       Impact factor: 4.313

5.  Site-specific N-glycan Analysis of Antibody-binding Fc γ Receptors from Primary Human Monocytes.

Authors:  Jacob T Roberts; Kashyap R Patel; Adam W Barb
Journal:  Mol Cell Proteomics       Date:  2019-12-30       Impact factor: 5.911

Review 6.  Tissues: the unexplored frontier of antibody mediated immunity.

Authors:  Nicholas E Webb; Biana Bernshtein; Galit Alter
Journal:  Curr Opin Virol       Date:  2021-02-10       Impact factor: 7.090

7.  Method for Identifying Galectin Ligands on Lymphocyte Membrane Glycoproteins.

Authors:  Kashyap R Patel; Adam W Barb; Sean R Stowell
Journal:  Methods Mol Biol       Date:  2022

8.  Site-Specific Glycosylation Mapping of Fc Gamma Receptor IIIb from Neutrophils of Individual Healthy Donors.

Authors:  Iwona Wojcik; Thomas Sénard; Erik L de Graaf; George M C Janssen; Arnoud H de Ru; Yassene Mohammed; Peter A van Veelen; Gestur Vidarsson; Manfred Wuhrer; David Falck
Journal:  Anal Chem       Date:  2020-09-22       Impact factor: 6.986

9.  Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation.

Authors:  Yusuke Mimura; Yuka Mimura-Kimura; Radka Saldova; Pauline M Rudd; Roy Jefferis
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 8.786

Review 10.  Fc γ receptor compositional heterogeneity: Considerations for immunotherapy development.

Authors:  Adam W Barb
Journal:  J Biol Chem       Date:  2020-11-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.